Candriam S.C.A. I Teos Therapeutics, Inc. Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

A detailed history of Candriam S.C.A. transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 769,213 shares of ITOS stock, worth $5.98 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

769,213

Previous 509,303 51.03%

Holding current value

$5.98 Million

Previous $7.56 Million 3.9%

% of portfolio

0.05%

Previous 0.05%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$10.09 - $17.97 $2.62 Million - $4.67 Million	259,910 Added 51.03%	769,213 $7.85 Million
Q2 2024 Aug 05, 2024	BUY	$10.33 - $18.09 $5.26 Million - $9.21 Million	509,303 New	509,303 $7.56 Million
Q3 2023 Nov 13, 2023	SELL	$10.95 - $14.6 $1.1 Million - $1.46 Million	-100,010 Reduced 16.35%	511,537 $5.6 Million
Q2 2023 Aug 08, 2023	SELL	$12.93 - $18.05 $1.65 Million - $2.31 Million	-127,970 Reduced 17.3%	611,547 $8.1 Million
Q3 2022 Nov 10, 2022	SELL	$18.6 - $27.25 $895,292 - $1.31 Million	-48,134 Reduced 6.11%	739,517 $14.1 Million
Q2 2022 Aug 03, 2022	BUY	$16.57 - $35.1 $1.72 Million - $3.64 Million	103,839 Added 15.19%	787,651 $16.2 Million
Q1 2022 May 13, 2022	SELL	$31.92 - $47.45 $2.35 Million - $3.49 Million	-73,515 Reduced 9.71%	683,812 $22 Million
Q4 2021 Feb 10, 2022	BUY	$26.23 - $47.86 $6.09 Million - $11.1 Million	232,083 Added 44.19%	757,327 $35.3 Million
Q3 2021 Nov 09, 2021	BUY	$23.91 - $29.58 $486,664 - $602,071	20,354 Added 4.03%	525,244 $14.2 Million
Q2 2021 Jul 20, 2021	BUY	$17.9 - $36.1 $9.04 Million - $18.2 Million	504,872 Added 2804844.5%	504,890 $13 Million
Q1 2021 Apr 29, 2021	BUY	$30.86 - $44.2 $555 - $795	18 New	18 $1,000

Others Institutions Holding ITOS

# of Institutions

166

Shares Held

36.6M

Call Options Held

1.95M

Put Options Held

374K

View Full List

About iTeos Therapeutics, Inc.

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $276M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

More about ITOS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account